Abstract 860: Effects of breastfeeding and oral contraception use on the risk of breast cancer recurrence: A multinational study

Conclusion: Our study suggests that breastfeeding decreases the risk of recurrence of breast cancer, while OCP usage increases the risk of recurrence of breast cancer. Further studies are needed to validate our results.canres;75/15_Supplement/860/table1T1Predictors of recurrence of breast cancer (rBC)Variablesβ EstimateAdjusted OR (CI)p-valueAge0.0221.02 (1.008-1.03)0.002Breastfed (BF, none vs.>3 children)1.062.9 (1.7-4.9) 3 children)0.742.09 (1.2-3.5)0.006Oral Contraceptive use (OCP, no vs. yes)-0.7430.47 (0.32-0.69)0.0001Radiation exposure (RE, no vs. yes)-1.310.26 (0.16- 0.13)
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Epidemiology Source Type: research

Related Links:

September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate canc...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
AbstractStudy questionDoes daily administration of letrozole during IVF stimulation affect endometrial thickness ?Summary answerPatients treated with letrozole during fresh IVF cycles had a thinner endometrium on the day of trigger compared to patients who did not receive letrozole.What is known alreadyLetrozole supplementation is commonly used during fertility preservation for breast cancer patients to reduce peak estrogen levels with no adverse effects on embryo outcomes. Studies in poor responders have found that letrozole use resulted in a shorter duration of stimulation and a lower total dose of gonadotropin, with no ...
Source: Human Reproduction - Category: Reproduction Medicine Source Type: research
AbstractPurpose of ReviewYoung women who carry a genetic predisposition to breast cancer need to balance surgical and nonsurgical risk reducing options with childbearing. In this review, we explore how women make decisions without the benefit of official guidelines and in the context of frequently contradictory strategies.Recent FindingsWomen of reproductive age with known BRCA mutations receive incomplete and conflicting advice regarding the urgency and timing of risk reducing mastectomy (RRM). Those who prioritize RRM achieve highly effective prevention and thereby avoid not only a diagnosis of breast cancer but also adj...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A c...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of life...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Researchers have developed a new ultrasound technique to monitor the placent...Read more on AuntMinnie.comRelated Reading: X-ray, CT reveal mummified ancient Egyptian was pregnant Fetal cardiovascular MRI helps diagnose congenital heart defects Lung ultrasound spots COVID-19 in newborns Pregnancy is safe for breast cancer survivors Imaging detects big, rare tumor protruding from fetus's mouth
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Jędrych Despite numerous studies evaluating the risk of breast cancer among oral contraception users, the effect of oral contraceptive on developing breast cancer remains inconclusive. Therefore, we conducted a systematic review of literature with meta-analysis in order to quantitative estimate this association. The bibliographic database MEDLINE and EMBASE, and reference lists of identified articles were searched, with no language restrictions, from the start of publication to August 2010. We performed a reanalysis and overall estimate of 79 case-control studies conducted between 1960–2010, including a total of...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Review Source Type: research
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); how...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Breast Cancer | Breastfed | Cancer | Cancer & Oncology | Children | Databases & Libraries | Epidemiology | Hormone Replacement Therapy | Hormones | Hysterectomy | Oral Cancer | Pregnancy | Pregnancy and Breast Cancer | Statistics | Study